Skip to search formSkip to main contentSkip to account menu

TAK-165

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

OxazolesTriazoles

Narrower (1)

mubritinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.
2016
2016
Inhibition of PI3K and mTOR Sensitises Oestrogen Receptor Positive Human Breast Cancer Cells to a Large Fraction of Radiation Dose
Resistance to radiotherapy has been attributed to the expression of proteins pertinent to cancer cell survival. Treatment… 
2016
2016
Evaluation of small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 for their radiomodulatory effects in human breast cancer cell lines
Intrinsic tumour radioresistance limits the benefit of radiotherapy. Targeted treatment modalities that are singly effective for… 
2015
2015
A Cocktail of Specific Inhibitors of HER-2, PI3K, and mTOR Radiosensitises Human Breast Cancer Cells
Intrinsic tumour radioresistance limits the benefit of radiotherapy. Targeted treatment modalities that are singly effective for… 
2006
2006
Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)